Nicola Hardwick
An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide
Hardwick, Nicola; Buchan, Sarah; Ingram, Wendy; Khan, Ghazala; Vittes, Gisella; Rice, Jason; Pulford, Karen; Mufti, Ghulam; Stevenson, Freda; Guinn, Barbara Ann
Authors
Sarah Buchan
Wendy Ingram
Ghazala Khan
Gisella Vittes
Jason Rice
Karen Pulford
Ghulam Mufti
Freda Stevenson
Dr Barbara Guinn B.Guinn@hull.ac.uk
Reader in Biomedical Sciences
Abstract
We have previously identified the novel Cancer/Testis antigen PASD1 by immunoscreening a testis library with pooled acute myeloid leukemia (AML) patient sera. To develop a cytotoxic T lymphocyte (CTL)-inducing vaccine, we have now investigated the carboxy-terminal region, known to contain serological determinants, for MHC class I (HLA-A*0201)-binding peptides. Algorithm-selected natural peptides failed to show detectable HLA-A*0201 binding in T2 assays. However, anchor-modified analogue peptides showed enhanced binding, with decreased off-rates. Analogue peptide-loaded antigen-presenting cells (APCs) induced IFN-γ production by T cells from normal donors and patients. In addition, peptide-specific T cells could be expanded from cancer patients by stimulation with the PASD1 analogue peptide Pa14. For clinical application, a DNA fusion gene vaccine encoding Pa14 was designed and tested in "humanized" mice. Splenocytes from vaccinated mice showed in vitro cytotoxicity against tumour cells, either exogenously loaded with the corresponding wild-type peptide (Pw8) or expressing endogenously processed PASD1 protein. We show for the first time that a DNA vaccine encoding an altered PASD1 epitope can induce CTLs to target the natural peptide expressed by human tumour cells. © 2013 by Barbara-ann Guinn.
Citation
Hardwick, N., Buchan, S., Ingram, W., Khan, G., Vittes, G., Rice, J., Pulford, K., Mufti, G., Stevenson, F., & Guinn, B. A. (2013). An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immunology Research, 13(3), 16-26. https://doi.org/10.1158/1424-9634.DCL-16.13.3
Journal Article Type | Article |
---|---|
Acceptance Date | Jul 1, 2013 |
Online Publication Date | Jul 15, 2013 |
Publication Date | Jul 19, 2013 |
Deposit Date | Apr 4, 2022 |
Publicly Available Date | Oct 27, 2022 |
Journal | Cancer Immunology Research |
Print ISSN | 2326-6066 |
Electronic ISSN | 2326-6074 |
Publisher | American Association for Cancer Research |
Peer Reviewed | Peer Reviewed |
Volume | 13 |
Issue | 3 |
Pages | 16-26 |
DOI | https://doi.org/10.1158/1424-9634.DCL-16.13.3 |
Keywords | PASD1; immunotherapy; acute myeloid leukemia; DNA vaccine; analogue peptide |
Public URL | https://hull-repository.worktribe.com/output/2596603 |
Publisher URL | https://aacrjournals.org/cancerimmun/article/13/3/16/471963/An-analogue-peptide-from-the-Cancer-Testis-antigen |
You might also like
Antigenic targets for the immunotherapy of acute myeloid leukaemia
(2019)
Journal Article
Urine biomarkers for the early detection of ovarian cancer – are we there yet?
(2019)
Journal Article
Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer
(2015)
Journal Article
PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies
(2013)
Journal Article
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search